Study of B/F/TAF in Participants Switching From CAB + RPV to B/F/TAF for HIV-1 Infection (EMPOWER)
Status:
Recruiting
Trial end date:
2025-05-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical study is to learn how safe and effective it is to switch to an oral
therapy of Bictegravir/Emtricitabine/Tenofovir (B/F/TAF) from Cabotegravir + Rilpivirine
(CAB+RPV) in participants living with virologically suppressed human immunodeficiency virus
type 1 (HIV-1), meaning participants with HIV RNA levels below detectable levels.
The primary objective of this study is to assess the safety of switching to B/F/TAF in
virologically suppressed participants unable/unwilling to continue on CAB+RPV intramuscular
(IM) injections or wishing to switch to oral therapy through Week 12.